Recombinant human IV-type collagen as well as preparation method and application thereof

By designing and expressing recombinant human type IV collagen with specific amino acid sequences in the E. coli expression system, the problem of difficult industrial production of type IV collagen recombinant expression is solved, high yield and stability are achieved, and cell migration and proliferation are promoted. , and verified its safety and stability.

CN119039425AActive Publication Date: 2024-11-29HEBEI NACO BIOTECHNOLOGY CO LTD

Patent Information

Application Number
CN202411316620.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-20
Publication Date
2024-11-29
Estimated Expiration
2044-09-20

AI Technical Summary

Technical Problem

In the prior art, the recombinant expression of type IV collagen is difficult to achieve industrial production, and the expression of full-length protein fails or the yield is low, resulting in difficulty in industrial production.

Method used

Design and express recombinant human type IV collagen with specific amino acid sequences, and is efficiently produced in the E. coli expression system through genetic engineering technology. Multiple cloning sites are used to connect to the pET30a(+) plasmid, and heat shock method is used to transform and induce expression. Purification by binding affinity chromatography and ion exchange chromatography yields high yield and stable recombinant proteins.

Benefits of technology

It has achieved high yield expression of recombinant human type IV collagen in the E. coli expression system, which is suitable for industrial production, and has verified that it has a promoting effect on cell migration, proliferation and adhesion, and has good safety and stability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The invention belongs to the technical field of optimized coding genes, and discloses a recombinant human IV-type collagen as well as a preparation method and application thereof, and the amino acid sequence of the recombinant human IV-type collagen is shown as SEQ ID No.1. Experiments prove that the collagen provided by the invention has the advantages of higher yield, better cell proliferation promoting performance, no cytotoxicity and high safety, and can be widely applied to the fields of medicines, medical instruments, biological materials, tissue engineering and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of optimized coding genes, and specifically relates to a recombinant human type IV collagen and a preparation method and application thereof. Background Art

[0002] Collagen is the most abundant protein in the body and the main structural protein of human tissues and organs, accounting for about 25%-35% of the total protein in the human body. It is also the main component of the extracellular matrix (ECM), accounting for about 85% of the extracellular matrix. It is commonly found in the skin, blood vessels, tendons, fascia and other parts, and plays an important role in maintaining the normal physiological functions of cells, tissues and organs and repairing injuries. In recent years, collagen has been regarded as a safe biomedical material because of its biocompatibility and low antigenicity that other polymer materials cannot match, and has been widely used in the pharmaceutical, health care and cosmetic industries. So far, there are at least 28 different types of collagen, which are located in different tissues and organs.

[0003] Members of the collagen family have a unique trimeric helical structure. Depending on whether they can form collagen fibrils with periodic striations, they are divided into fibrillar collagen and nonfibrillar collagen. Common fibrillar collagens include type I, II, III, V and XI collagens, and common nonfibrillar collagens include type IV and X collagens. Type IV collagen is mainly present in the basement membrane and plays an important role in the formation of the extracellular matrix and the regulation of cell function. Type IV collagen not only provides a scaffold for cell growth, but also can recognize and interact with specific receptors on the cell surface, thereby activating intracellular signal transduction pathways and participating in important physiological processes such as cell adhesion, migration, growth, proliferation and differentiation. The lack of type IV collagen can lead to abnormalities in the structure and function of the basement membrane, thereby affecting the normal physiological activities of cells.

[0004] At present, the sources of collagen are mainly extracted from animal tissues and expressed by genetic engineering technology. The content of type IV collagen in animals is low. Traditionally, type IV collagen is separated from human placenta and purified using a multi-step process. This collagen extraction method has certain limitations, such as low extraction efficiency and low purity. Recombinant collagen mainly has the advantages of processability, no virus hidden dangers, good water solubility, batch stability and low rejection reaction. Therefore, the use of genetic engineering technology to produce type IV collagen is bound to be the best choice. Unfortunately, some problems have been encountered: the recombinant expression of the full length of type IV collagen has not been successful. Although some truncated proteins of type IV collagen can be recombinantly expressed, the yield is not high and / or the biological activity is much worse than the full length of type IV collagen, so it is not suitable for industrial-scale production (as disclosed in CN 117903287 A).

[0005] In view of this, there is a need in the art for a recombinantly expressed human type IV collagen that has good stability and can be prepared in large quantities in an industrial system. Summary of the invention

[0006] The purpose of the present invention is to overcome the defects in the prior art, provide a recombinant human type IV collagen with good stability that can be industrially produced, and also provide a preparation method and application thereof.

[0007] To achieve the above object, the technical solution adopted by the present invention is: In one aspect, the present invention provides a recombinant human type IV collagen, wherein the recombinant collagen comprises one or more of the following characteristics: (1) Its amino acid sequence is shown in SEQ ID No. 1, which is as follows: MGVKGEAGLPGTPGPTGPAGQKGEPGSDGIPGSAGEKGEPGLPGRGFPGFPGAKGDKGSKGEVGFPGLAGSPGIPGSKGEQGFMGPPGPQGQPGLPGSPGHATEGP KGDRGPQGQPGLPGLPGPMGPPGLPGIDGVKGDKGNPGWPGAPGVPPGPKGDPGFQGMPGIGGSPGITGSKGDMGPPGVPGFQGPKGLPGLQGIKGDQGDQGHHHHHHH (2) Its amino acid sequence is modified by substitution, deletion or addition of one or more amino acids based on SEQ ID No.1; (3) An amino acid sequence that is more than 80% identical to the amino acid sequence shown in SEQ ID No: 1.

[0008] In another aspect, the present invention provides a nucleic acid encoding the above-mentioned recombinant human type IV collagen, wherein the nucleotide sequence of the recombinant human type IV collagen comprises one or more of the following features: (1) The nucleotide sequence is shown in SEQ ID No. 2, which is as follows: ATGGGCGTTAAAGGCGAAGCCGGTTTACCGGGCACCCCGGGTCCGACGGGCCCGGCGGGCCAAAAGGGCGAACCGGGCAGCGATGGCATCCCGGGCAGCGCGGGCGAAAAAGGCGAACCGGGCTTACCGGGCCGCGGTTTTCCGGGCTTCCCGGGCGCGA AAGGCGATAAAGGTAGCAAAGGCGAGGTTGGCTTTCCGGGTCTGGCGGGCAGTCCGGGCATTCCGGGTAGCAAAGGTGAACAAGGCTTCATGGGTCCACCGGGTCCGCAAGGTCAGCCGGGCTTACCGGGCAGTCCGGGCCATGCCACGGAGGGGCCCAAAA GGCGATCGCGGCCCACAAGGCCAACCGGGCTTACCGGGTCTGCCGGGTCCGATGGGTCCACCGGGCCTGCCGGGCATTGATGGCGTGAAAGGTGACAAAGGTAACCCGGGTTGGCCGGGCGCGCCGGGCGTGCCGGGCCCGAAAGGCGATCCGGGTTTTC AAGGCATGCCGGGCATCGGCGGCAGCCCGGGCATTACCGGCAGCAAAGGCGATATGGGTCCGCCGGGCGTTCCGGGCTTTCAAGGCCCGAAAGGCTTACCGGGCTTACAAGGCATTAAAGGCGATCAAGGCGATCAAGGCCATCACCATCACCATCATTAA (2) Any nucleotide sequence obtained by replacing synonymous codons in (1).

[0009] In yet another aspect, the present invention provides a vector comprising any one or more of the above-mentioned nucleic acids.

[0010] In still another aspect, the present invention provides a host cell, wherein the host cell contains the above-mentioned vector.

[0011] In another aspect, the present invention provides a method for preparing the above-mentioned recombinant human type IV collagen, which specifically comprises the following steps: (1) Protein sequence design Based on human type IV collagen, an amino acid sequence as shown in SEQ No. 1 was designed; (2) Gene design and synthesis Reversely designing a nucleic acid sequence encoding the recombinant human type IV collagen according to the amino acid sequence of the recombinant human type IV collagen described in step (1), and performing codon optimization to obtain a nucleotide sequence encoding the recombinant human type IV collagen, and then performing gene synthesis to obtain a nucleic acid fragment encoding the recombinant human type IV collagen fragment; (3) Construction of expression vector: The expression plasmid was obtained by ligating the plasmid to the pET30a(+) plasmid via the NdeI and XhoI multiple cloning sites; (4) Construction and screening of expression strains: The plasmid described in step (3) is transferred into the host cell competent state by heat shock method, spread on a resistance plate containing kanamycin, and cultured to obtain an expression strain; (5) Inducible expression Inducing the expression strain obtained in step (4) to express, and collecting the bacterial solution; (6) Purification The bacterial liquid collected in step (5) is subjected to bacterial cell disruption and centrifugation, affinity chromatography, ion exchange chromatography, desalting, and freeze-drying to obtain a freeze-dried product of recombinant human type IV collagen.

[0012] As some preferred embodiments of the present invention, the host cell is Escherichia coli BL21 (DE3).

[0013] In another aspect, the present invention provides a use of the above-mentioned recombinant human type IV collagen in cosmetics, medicines, health products, medical devices or biomaterials.

[0014] The beneficial effects of adopting the above technical solution are: (1) The recombinant human type IV collagen provided by the present invention can be expressed in an Escherichia coli expression system with high expression yield, and is suitable for industrial large-scale production.

[0015] (2) The recombinant human type IV collagen provided by the present invention has been verified by experiments to have good effects in promoting cell migration and proliferation, and has good safety and stability. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] In order to more clearly illustrate the technical solutions in the specific implementation manner of the present invention, the drawings required for describing the specific implementation manner are briefly introduced below.

[0017] Figure 1Electrophoresis of the sample of the recombinant human type IV collagen HC84 prepared in Example 5 during affinity chromatography; Figure 2 Electrophoresis of the sample of the recombinant human type IV collagen HC84 prepared in Example 5 during ion chromatography; Figure 3 This is a statistical chart of the cytotoxicity experimental data of recombinant human IV collagen HC84 at different concentrations in effect example 1; Figure 4 This is a statistical chart of the data of the cell proliferation promotion test of recombinant human IV collagen HC84 in effect example 2; Figure 5 This is a statistical chart of the data of the cell migration promotion test of recombinant human IV collagen HC84 in effect example 3; Figure 6 This is a statistical chart of the data of the recombinant human IV collagen HC84 cell adhesion test in effect example 4; Figure 7 This is the electrophoresis diagram of the recombinant human IV collagen HC84 cell stability test sample in effect example 5; DETAILED DESCRIPTION

[0018] In order to make the objectives, technical solutions and advantages of the present invention more clear, the present invention is clearly and completely described below in conjunction with specific embodiments.

[0019] Example 1 Gene Design and Synthesis (1) Genetic design: According to the sequence characteristics of human type IV collagen, the collagen sequence HC84 was designed, and its amino acid sequence is shown in SEQ ID NO.1. Its N-terminus starts with methionine to reduce the degradation rate of the protein, and a histidine tag is added to the C-terminus to facilitate identification and purification. The amino acid sequence of the recombinant human type IV collagen fragment is shown below: SEQ ID NO.1 MGVKGEAGLPGTPGPTGPAGQKGEPGSDGIPGSAGEKGEPGLPGRGFPGFPGAKGDKGSKGEVGFPGLAGSPGIPGSKGEQGFMGPPGPQGQPGLPGSPGHAT EGPKGDRGPQGQPGLPGLPGPMGPPGLPGIDGVKGDKGNPGWPGAPGVPPGPKGDPGFQGMPGIGGSPGITGSKGDMGPPGVPGFQGPKGLPGLQGIKGDQGDQG HHHHHH The coding nucleic acid sequence was reversely designed using the online design tool Jcat (http: / / www.jcat.de / ), and codon optimization was performed for host E. coli expression. After the above optimization, the corresponding nucleic acid fragment encoding recombinant human type IV collagen was obtained, and the nucleotide sequence corresponding to the above amino acid sequence is shown in SEQ ID NO.2: ATGGGCGTTAAAGGCGAAGCCGGTTTACCGGGCACCCCGGGTCCGACGGGCCCGGCGGGCCAAAAGGGCGAACCGGGCAGCGATGGCATCCCGGGCAGCGCGGGCGAAAAAGGCGAACCGGGCTTACCGGGCCGCGGTTTTCCGGGCTTCCCGGGCGCGA AAGGCGATAAAGGTAGCAAAGGCGAGGTTGGCTTTCCGGGTCTGGCGGGCAGTCCGGGCATTCCGGGTAGCAAAGGTGAACAAGGCTTCATGGGTCCACCGGGTCCGCAAGGTCAGCCGGGCTTACCGGGCAGTCCGGGCCATGCCACGGAGGGGCCCAAAA GGCGATCGCGGCCCACAAGGCCAACCGGGCTTACCGGGTCTGCCGGGTCCGATGGGTCCACCGGGCCTGCCGGGCATTGATGGCGTGAAAGGTGACAAAGGTAACCCGGGTTGGCCGGGCGCGCCGGGCGTGCCGGGCCCGAAAGGCGATCCGGGTTTTC AAGGCATGCCGGGCATCGGCGGCAGCCCGGGCATTACCGGCAGCAAAGGCGATATGGGTCCGCCGGGCGTTCCGGGCTTTCAAGGCCCGAAAGGCTTACCGGGCTTACAAGGCATTAAAGGCGATCAAGGCGATCAAGGCCATCACCATCACCATCATTAA (2) Gene synthesis: Based on the nucleic acid sequence shown above, a nucleic acid fragment encoding a recombinant human type IV collagen fragment was synthesized by GenScript Biotech Co., Ltd.

[0020] Example 2 Construction of expression vector pET30a(+)-HC84 The nucleic acid fragment SEQ ID NO.2 obtained in Example 1 was ligated to the pET30a(+) plasmid (via the NdeI and XhoI multiple cloning sites) to obtain the recombinant plasmid pET30a(+)-HC84.

[0021] Example 3 Construction of expression strain BL21(DE3) / pET30a(+)-HC84 The construction of the expression strain refers to the method described in the "Molecular Cloning Laboratory Guide (3rd Edition)" (written by J. Sambrook et al.), and the specific steps are as follows: pick a single colony of Escherichia coli BL21 (DE3) and inoculate it into an LB test tube, then culture it at 37°C with shaking overnight; add 0.5ml of the overnight culture solution to a conical flask containing 50ml LB, and culture it at 37°C with vigorous shaking for about 2 hours to allow the bacteria to grow to the early logarithmic phase; transfer the bacteria to an ice-cold 50ml polypropylene tube under sterile conditions and place it on ice for 10 minutes; centrifuge at 4°C, 4000rpm, pour out the supernatant, and invert the tube to allow the residual liquid to flow out as much as possible; add 6ml of ice-cold 0.1mol / L CaCl2 to resuspend the precipitate, and place it on ice for 30 minutes; centrifuge at 4°C, 3000rpm, pour out the supernatant, and invert the tube to allow the residual liquid to flow out as much as possible; add 1.2ml of ice-cold 0.1mol / L Resuspend the precipitate with CaCl2 (if you want to prepare competent cells for storage at -70°C, add 0.1 mol / L CaCl2 containing 20% ​​glycerol to suspend the bacteria), place it at 4°C for 5 to 24 hours, then take 200 μl of the competent cell suspension, add the recombinant plasmid pET30a(+)-HC84 prepared in Example 2 (volume <10 μl, DNA <50 ng), mix gently, and place it on ice for 30 minutes; heat shock it in a 42°C water bath for 90 seconds, and immediately put it on ice to cool; add 500 μl of liquid LB culture medium, mix it, and put it in a 37°C shaker for low-speed shaking to recover for 45 minutes (it can also be directly put into a 37°C water bath for recovery for 1 hour after adding LB, and the tube is shaken in the middle to suspend the cells); take the transformed cells and spread them on a plate with antibiotics (kanamycin), place it in a 37°C incubator and invert it for culture, and the colonies grown are the expression strain BL21(DE3) / pET30a(+)-HC84.

[0022] Example 4 Induced expression of expression strain BL21(DE3) / pET30a(+)-HC84 A single colony of the expression strain BL21(DE3) / pET30a(+)-HC84 prepared in Example 3 was selected and placed in LB liquid medium containing 50 μg / mL Kan. After culturing overnight at 37°C and 200 r / min, it became an activated seed. Then, it was inoculated into a 5L fermenter containing 3L CM medium at a 3% inoculum. The fermentation process was controlled at 37°C, 30% dissolved oxygen, and pH 7.0. When OD600 When the expression reached 60, IPTG (isopropyl-β-D-thiogalactoside) was added to a final concentration of 0.5 mM to induce expression, and the culture was continued for 12 hours, and the cells were collected by centrifugation.

[0023] Example 5 Purification of recombinant human type IV collagen HC84 The theoretical isoelectric point of HC84 is 7.07 and the theoretical molecular weight is 20.04 kDa. Recombinant human type IV collagen was purified using Ni affinity chromatography column and ion exchange chromatography column. The specific purification steps are as follows: 1. Breaking bacteria 1 kg of the bacterial cells prepared in Example 4 were resuspended in an appropriate amount of a lysis solution (20 mM Tris 500 mM NaCl, 20 mM imidazole, pH 8.5), with the ratio (m / v) of bacterial cells to lysis solution being 1:10-1:20, and 1:10 was selected in this example. The bacterial cells were ruptured using a high-pressure homogenizer. The ruptured bacterial solution was centrifuged at 12000 g for 1 h, and the supernatant was collected and filtered using a 0.45 μm filter membrane.

[0024] 2. Affinity chromatography (1) Column balance: The Ni Sepharose FF column was equilibrated with buffer A (20 mM Tris, 500 mM NaCl, 20 mM imidazole, pH 8.5) until the baseline was stable.

[0025] (2) Loading: The supernatant was added to the chromatography column, and the column retention time was controlled to be no less than 5 min.

[0026] (3) Column flushing: Rinse the column with buffer A until the baseline is stable and not less than 7 CV.

[0027] (4) Target protein elution: The solution was eluted with 80% Buffer A and 20% Buffer B (20 mM Tris, 500 mM NaCl, 500 mM imidazole, pH 8.5), and the eluate was collected into a new centrifuge tube to obtain a solution containing recombinant human type IV collagen HC84.

[0028] 3. Ion exchange chromatography (1) Sample processing: The affinity chromatography eluate was diluted with buffer C (20 mM Tris, pH 5.5) or ultrafiltered to a conductivity of less than 5 mS / cm.

[0029] (2) Column balance: The SP Chromstar FF column was equilibrated with buffer C for 5 CVs until the baseline was stable.

[0030] (3) Loading: The replacement liquid is added to the chromatography column, and the column retention time is controlled to be no less than 5 minutes.

[0031] (4) Column flushing: Rinse the column with buffer C until the baseline is stable and not less than 7 CV.

[0032] (5) Target protein elution: The solution was eluted with 60% Buffer C and 40% Buffer D (20 mM Tris, 1 M NaCl, pH 5.5), and the eluate was collected into a new centrifuge tube to obtain a solution containing recombinant human type IV collagen HC84.

[0033] 4. Desalination The HC84 solution obtained in step 3 was replaced with purified water using a 5 kDa ultrafiltration membrane pack device by concentration followed by replacement or equal volume replacement to remove salt from the solution, and lyophilized to obtain a lyophilized product of recombinant collagen. 20 g of lyophilized product was obtained from 1 kg of bacterial cells.

[0034] Example 6 SDS-PAGE protein electrophoresis detection Sample treatment: Collect the affinity chromatography process samples and ion chromatography process samples in Example 5, add loading buffer and mix evenly, place in a metal bath at 100°C for 5 minutes, cool naturally, and set aside. Select GenScript SurePAGE™ precast gel (4-12%) for sample loading, and perform electrophoresis at 140 V for 45-55 minutes until the bromophenol blue band runs to the bottom of the gel.

[0035] Coomassie Brilliant Blue R-250 staining using a microwave oven: (1) Prepare the staining solution: Dissolve Coomassie Brilliant Blue R-250 to a final concentration of 0.1% (W / V) in 40% ethanol and 10% acetic acid solution; (2) Prepare the destaining solution: Dissolve 10% (V / V) ethanol and 7.5% (V / V) acetic acid together; (3) After electrophoresis is completed, pry open the gel sheet, remove the gel, and then place it in a staining container containing 100 ml of staining solution; (4) Cover the container with a lid and place it in a microwave oven and heat it on high for 8 minutes. To avoid danger, be careful not to let the solution boil; (5) Remove the staining container from the microwave and place it on a decolorizing shaker at room temperature for 5 minutes; (6) Pour out the staining solution and carefully wash the gel with deionized water; (7) Pour out the deionized water and add 100 ml of decolorizing solution; (8) Cover the container with a lid and place it in a microwave oven on high heat for 8 minutes; (9) Pour out the decolorizing solution, add new decolorizing solution, and repeat step 8; (10) Remove from the microwave and place it on a decolorizing shaker at room temperature and gently shake until the background is clear.

[0036] The results are shown in the attached figure Figure 1 and 2 shown.

[0037] Effect Example 1 Cytotoxicity Experiment of Recombinant Human Type IV Collagen HC84 The cytotoxicity of HC84 was evaluated according to the method specified in the MTT cytotoxicity test in Appendix C of GB / T 16886.5-2017 Biological Evaluation of Medical Devices Part 5: In Vitro Cytotoxicity Test. The experiment was divided into four groups: sample group (recombinant human type IV collagen HC74 solution prepared in Example 5), positive control group (extract of ZDEC Polyurethane Film), negative control group (extract of High Density Polyethylene Film), and medium control group (cell culture medium containing 10% serum, placed at 37±1°C, 24±2h). L929 cells were cultured in the extract or cell culture medium described in each group, and the relative cell proliferation rate was calculated when the negative control group and the positive control group met the requirements. Figure 3 As shown, HC84 had no obvious cytotoxicity in the concentration range of 0.1 mg / ml~10 mg / ml.

[0038] Effect Example 2 Recombinant human type IV collagen HC84 promotes cell proliferation test HaCaT skin keratinocytes were cultured at 5×10 3 / well for cell inoculation. After the 96-well culture plate was inoculated with cells, it was placed in a 37 ℃, 5% CO2 incubator and cultured for 24 h, 48 h, and 72 h, respectively. The culture fluid in the wells was discarded, 100 μL of culture medium was added to each well of the blank control group, and 100 μL of HC84 solution was added to each well of the sample group. The 96-well culture plate was placed in a 37 ℃, 5% CO2 incubator and cultured for 24 h, 48 h, and 72 h. 10 μL of CCK8 reagent was added to each well and placed in the incubator for incubation for 2 h. After incubation, the absorbance value of each well at a wavelength of 450 nm was detected using an enzyme-labeled instrument. Figure 4 As shown, recombinant human type IV collagen HC84 has a good cell proliferation effect.

[0039] Effect Example 3 Recombinant human type IV collagen HC84 promotes cell migration test According to the Appendix C of the "Pharmaceutical Industry Standard of the People's Republic of China" YY / T1849-2022 Recombinant Collagen: Cell Migration Test-Cell Scratch Method, the effect of recombinant type IV humanized collagen HC84 on the migration rate of HaCaT skin keratinocytes was evaluated. The cells were digested and counted, and 5×10 cells were seeded in each well of a six-well plate. 5 HaCaT skin keratinocytes were cultured in a total volume of 2 mL per well at 37°C and 5% CO 2 After 24 hours of culture, use a 200 μL pipette tip to align the plate vertically with a ruler, push down gently to form a scratch on the longitudinal (horizontal) line, rinse the cells three times with PBS, and remove the scratched cells; the sample group (adding 2, 4, 6, 8, 10 mg / ml HC84) added 2 ml of serum-free medium, and the blank control group only added serum-free medium. Take pictures under a microscope at 0h, 24h, 48h, and 72h of culture, and calculate the cell migration rate of each group. Figure 5 As shown, compared with the control group, HC84 significantly induced the migration of HaCaT cells in a time-dependent manner.

[0040] Effect Example 4 Recombinant human type IV collagen HC84 cell adhesion test HaCaT skin keratinocytes were digested and counted, and 1 × 10 cells were seeded per well in a 96-well plate. 5HaCaT skin keratinocytes, 100 μL / well. The blank control group (BC) only added PBS, the sample group (added 2, 4, 6, 8, 10 mg / ml HC84), and the positive control group (PC, sample maximum enzyme activity control group). The culture medium was discarded, and the samples were washed once with PBS buffer and treated for 24 hours (5% CO2 37℃ >90% humidity). One hour before the scheduled detection time, the "sample maximum enzyme activity control well" was treated with LDH release reagent. The amount added was 10% of the original culture medium volume. After adding the LDH release reagent, repeatedly blow and mix, and continue incubation; when the scheduled time comes, the cell culture plate is centrifuged at 400 g in a multi-well centrifuge for 5 min. Take 120 μL of supernatant in a new 96-well plate; add 60 μL of LDH detection solution to each well, mix, and incubate at room temperature away from light for 30 min; the absorbance value is measured at 490 nm. The results are as follows Figure 6 As shown, compared with the control group, HC84 at concentrations of 2 mg / ml and 4 mg / ml has the ability to increase the level of LDH secreted by HaCaT cells, thereby improving the ability of cell adhesion.

[0041] Effect Example 5 Stability Test of Recombinant Human Type IV Collagen HC84 Take 10 mg of each of the freeze-dried product samples from the same batch stored at room temperature for 3, 6, and 12 months, dissolve in 1 ml of ultrapure water, and perform SDS-PAGE protein electrophoresis detection. Figure 7 As shown, recombinant human type IV collagen HC84 has good stability.

[0042] The above embodiment provides a recombinant human type IV collagen that can be produced in a process-based manner. The effect examples show that the recombinant human type IV collagen has no cytotoxicity and can promote the proliferation of L929 mouse fibroblasts.

[0043] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. A recombinant human type IV collagen, characterized in that: Its amino acid sequence is shown in SEQ ID No.

1.

2. A nucleic acid encoding the recombinant human type IV collagen according to claim 1, characterized in that: The nucleotide sequence of the recombinant human type IV collagen is shown in SEQ ID No.

2.

3. A carrier, characterized in that The vector contains the nucleic acid according to claim 2.

4. A host cell, characterized in that The host cell contains the vector according to claim 3.

5. A method for preparing the recombinant human type IV collagen as claimed in claim 1, characterized in that: The specific steps include: (1) Protein sequence design Based on human type IV collagen, an amino acid sequence as shown in SEQ No. 1 was designed; (2) Gene design and synthesis Reversely designing a nucleic acid sequence encoding the recombinant human type IV collagen according to the amino acid sequence of the recombinant human type IV collagen described in step (1), and performing codon optimization to obtain a nucleotide sequence encoding the recombinant human type IV collagen, and then performing gene synthesis to obtain a nucleic acid fragment encoding the recombinant human type IV collagen fragment; (3) Construction of expression vector: The expression plasmid was obtained by ligating the plasmid to the pET30a(+) plasmid via the NdeI and XhoI multiple cloning sites; (4) Construction and screening of expression strains: The plasmid described in step (3) is transferred into the host cell competent state by heat shock method, spread on a resistance plate containing kanamycin, and cultured to obtain an expression strain; (5) Inducible expression Inducing the expression strain obtained in step (4) to express, and collecting the bacterial solution; (6) Purification The bacterial liquid collected in step (5) is subjected to bacterial cell disruption and centrifugation, affinity chromatography, ion exchange chromatography, desalting, and freeze-drying to obtain a freeze-dried product of recombinant human type IV collagen.

6. The preparation method according to claim 5, characterized in that: The host cell is Escherichia coli BL21 (DE3).

7. Use of the recombinant human type IV collagen as claimed in claim 1 in the preparation of pharmaceutical products, medical devices, biomaterials and tissue engineering.

Citation Information

Patent Citations

  • Recombinant human III-type collagen as well as preparation method and application thereof

    CN114671946A

  • Recombinant human IV type collagen and preparation method thereof

    CN117801095A

  • Water-soluble recombinant human X VII type collagen as well as preparation method and application thereof

    CN117801096A

  • Recombinant human II-type collagen as well as preparation method and application thereof

    CN118359701A

Cited By

  • Recombinant IV type collagen as well as preparation method and application thereof

    CN119751647A

  • Recombinant type IV collagen and its preparation method and application

    CN119751647B

  • Recombinant humanized IV-type collagen M2 or M4 as well as preparation method and application thereof

    CN119979549A

  • Recombinant human VI-type collagen as well as coding gene and expression method thereof

    CN120192401A

  • A recombinant human collagen type VI, its encoding gene and expression method

    CN120192401B